STAT May 22, 2024
Matthew Herper, Elaine Chen

Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
Kroger partners with Express Scripts to expand pharmacy services
Denali’s Data in Rare Enzyme Deficiency Keep It on Pace to Seek Speedy FDA Approval
Vertex challenger Sionna prices $191M IPO
Some of the Biggest Healthcare Stories from 2024 Involved Pharmacy. What’s Next in 2025?
Insights from JP Morgan 2025: Key trends shaping the pharma industry

Share This Article